Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Feb. 24, 2015, 75 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $542.19 to $168,250,000.00.

Highlighted Stocks Traded by Insiders:

Under Armour (UA) - FREE Research Report

Mirchin Matthew C, who is President of North America at Under Armour, sold 12,000 shares at $75.88 on Feb. 24, 2015. Following this transaction, the President of North America owned 52,621 shares meaning that the stake was reduced by 18.57% with the 12,000-share transaction.

The shares most recently traded at $77.11, up $1.23, or 1.59% since the insider transaction. Historical insider transactions for Under Armour go as follows:

  • 4-Week # shares sold: 108,920
  • 12-Week # shares sold: 108,920
  • 24-Week # shares sold: 149,344

The average volume for Under Armour has been 2.3 million shares per day over the past 30 days. Under Armour has a market cap of $13.5 billion and is part of the consumer goods sector and consumer non-durables industry. Shares are up 11.27% year-to-date as of the close of trading on Tuesday.

Under Armour, Inc., together with its subsidiaries, develops, markets, and distributes branded performance apparel, footwear, and accessories for men, women, and youth primarily in North America, Europe, the Middle East, Africa, Asia, and Latin America. The company has a P/E ratio of 79.9. Currently, there are 12 analysts who rate Under Armour a buy, 1 analyst rates it a sell, and 12 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on UA - FREE

TheStreet Quant Ratings

rates Under Armour as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and solid stock price performance. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full

Under Armour Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Cinemark Holdings (CNK) - FREE Research Report

Bunnell Steve, who is EVP - Global Content Prog at Cinemark Holdings, sold 8,360 shares at $41.89 on Feb. 24, 2015. Following this transaction, the EVP - Global Content Prog owned 77,266 shares meaning that the stake was reduced by 9.76% with the 8,360-share transaction.

The shares most recently traded at $41.44, down $0.45, or 1.09% since the insider transaction. Historical insider transactions for Cinemark Holdings go as follows:

  • 4-Week # shares sold: 25,000
  • 12-Week # shares sold: 25,000
  • 24-Week # shares sold: 25,000

The average volume for Cinemark Holdings has been 709,700 shares per day over the past 30 days. Cinemark Holdings has a market cap of $4.8 billion and is part of the services sector and media industry. Shares are up 17.12% year-to-date as of the close of trading on Tuesday.

Cinemark Holdings, Inc., together with its subsidiaries, is engaged in motion picture exhibition business. The company operates theatres in the United States, Brazil, Argentina, Chile, Colombia, Peru, Ecuador, Honduras, El Salvador, Nicaragua, Costa Rica, Panama, and Guatemala. The stock currently has a dividend yield of 2.39%. The company has a P/E ratio of 25.2. Currently, there are 11 analysts who rate Cinemark Holdings a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CNK - FREE

TheStreet Quant Ratings

rates Cinemark Holdings as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and notable return on equity. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full

Cinemark Holdings Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Celsion (CLSN) - FREE Research Report

EGWU, Inc. fka EGEN, Inc., who is 10% Owner at Celsion, sold 199,765 shares at $3.30 on Feb. 24, 2015. Following this transaction, the 10% Owner owned 2.5 million shares meaning that the stake was reduced by 7.37% with the 199,765-share transaction.

The shares most recently traded at $3.01, down $0.29, or 9.63% since the insider transaction. Historical insider transactions for Celsion go as follows:

  • 4-Week # shares bought: 4,000
  • 12-Week # shares bought: 4,000
  • 24-Week # shares bought: 8,000

The average volume for Celsion has been 205,100 shares per day over the past 30 days. Celsion has a market cap of $61.1 million and is part of the health care sector and drugs industry. Shares are up 26.61% year-to-date as of the close of trading on Tuesday.

Celsion Corporation, an oncology drug development company, focuses on the development and commercialization of chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. Currently, there are 3 analysts who rate Celsion a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CLSN - FREE

TheStreet Quant Ratings

rates Celsion as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full

Celsion Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by

Zacks Investment Research

null